Production of interleukin-1 and tumor necrosis factor by cisplatin-treated murine peritoneal macrophages

R. Kumar Singh, A. Sodhi, S. Mahendra Singh

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Supernatants collected from cisplatin-treated macrophages demonstrated enhanced cytotoxicity against actinomycin-D-treated L929 cells and also enhanced the thymocyte proliferation in response to concanavalin A, showing that cisplatin-treated macrophages release interleukin-1 (IL-1) and tumor necrosis factor (TNF) into the culture supernatant. The supernatant collected from untreated macrophages showed little TNF and IL-1 activity. The release of TNF and IL-1 was observed to be dependent on the dose and duration of cisplatin treatment. Medium alone containing cisplatin did not enhance thymocyte proliferation and had little cytotoxic effect on actinomycin-D-treated L929 cells. Cisplatin-treated macrophage culture supernatants were chromatographed over a Superose 12 column on an FPLC system. TNF activity eluted in two major peaks with apparent molecular weights of 50-55 and 15-20 kilodaltons, respectively. The kinetics of IL-1 release was also studied. Maximum production and release of IL-1 were observed up to 24 h after cisplatin treatment and then gradually declined. Freeze-thaw lysates of cisplatin-treated macrophages also showed enhanced IL-1 activity. Paraformaldehyde (PFA)-fixed cisplatin-treated macrophages showed significantly enhanced cytotoxic activity against L929 cells as compared to PFA-fixed untreated macrophages. PFA-fixed cisplatin-treated macrophages also enhanced thymocyte proliferation. These results suggest that cisplatin treatment of murine macrophages also results in increased expression of membrane-associated lL- 1 and TNF activity.

Original languageEnglish (US)
Pages (from-to)105-116
Number of pages12
JournalNatural Immunity and Cell Growth Regulation
Volume10
Issue number2
StatePublished - Jun 3 1991

Fingerprint

Macrophages
Peritoneal Macrophages
Interleukin-1
Cisplatin
Tumor Necrosis Factor-alpha
Thymocytes
Dactinomycin
Cell culture
Cytotoxicity
Concanavalin A
Molecular Weight
Molecular weight
Membranes
Kinetics

ASJC Scopus subject areas

  • Immunology
  • Clinical Biochemistry

Cite this

Production of interleukin-1 and tumor necrosis factor by cisplatin-treated murine peritoneal macrophages. / Kumar Singh, R.; Sodhi, A.; Mahendra Singh, S.

In: Natural Immunity and Cell Growth Regulation, Vol. 10, No. 2, 03.06.1991, p. 105-116.

Research output: Contribution to journalArticle

@article{ee08fb889e2442008b3e9d9594273eed,
title = "Production of interleukin-1 and tumor necrosis factor by cisplatin-treated murine peritoneal macrophages",
abstract = "Supernatants collected from cisplatin-treated macrophages demonstrated enhanced cytotoxicity against actinomycin-D-treated L929 cells and also enhanced the thymocyte proliferation in response to concanavalin A, showing that cisplatin-treated macrophages release interleukin-1 (IL-1) and tumor necrosis factor (TNF) into the culture supernatant. The supernatant collected from untreated macrophages showed little TNF and IL-1 activity. The release of TNF and IL-1 was observed to be dependent on the dose and duration of cisplatin treatment. Medium alone containing cisplatin did not enhance thymocyte proliferation and had little cytotoxic effect on actinomycin-D-treated L929 cells. Cisplatin-treated macrophage culture supernatants were chromatographed over a Superose 12 column on an FPLC system. TNF activity eluted in two major peaks with apparent molecular weights of 50-55 and 15-20 kilodaltons, respectively. The kinetics of IL-1 release was also studied. Maximum production and release of IL-1 were observed up to 24 h after cisplatin treatment and then gradually declined. Freeze-thaw lysates of cisplatin-treated macrophages also showed enhanced IL-1 activity. Paraformaldehyde (PFA)-fixed cisplatin-treated macrophages showed significantly enhanced cytotoxic activity against L929 cells as compared to PFA-fixed untreated macrophages. PFA-fixed cisplatin-treated macrophages also enhanced thymocyte proliferation. These results suggest that cisplatin treatment of murine macrophages also results in increased expression of membrane-associated lL- 1 and TNF activity.",
author = "{Kumar Singh}, R. and A. Sodhi and {Mahendra Singh}, S.",
year = "1991",
month = "6",
day = "3",
language = "English (US)",
volume = "10",
pages = "105--116",
journal = "Natural Immunity and Cell Growth Regulation",
issn = "0254-7600",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Production of interleukin-1 and tumor necrosis factor by cisplatin-treated murine peritoneal macrophages

AU - Kumar Singh, R.

AU - Sodhi, A.

AU - Mahendra Singh, S.

PY - 1991/6/3

Y1 - 1991/6/3

N2 - Supernatants collected from cisplatin-treated macrophages demonstrated enhanced cytotoxicity against actinomycin-D-treated L929 cells and also enhanced the thymocyte proliferation in response to concanavalin A, showing that cisplatin-treated macrophages release interleukin-1 (IL-1) and tumor necrosis factor (TNF) into the culture supernatant. The supernatant collected from untreated macrophages showed little TNF and IL-1 activity. The release of TNF and IL-1 was observed to be dependent on the dose and duration of cisplatin treatment. Medium alone containing cisplatin did not enhance thymocyte proliferation and had little cytotoxic effect on actinomycin-D-treated L929 cells. Cisplatin-treated macrophage culture supernatants were chromatographed over a Superose 12 column on an FPLC system. TNF activity eluted in two major peaks with apparent molecular weights of 50-55 and 15-20 kilodaltons, respectively. The kinetics of IL-1 release was also studied. Maximum production and release of IL-1 were observed up to 24 h after cisplatin treatment and then gradually declined. Freeze-thaw lysates of cisplatin-treated macrophages also showed enhanced IL-1 activity. Paraformaldehyde (PFA)-fixed cisplatin-treated macrophages showed significantly enhanced cytotoxic activity against L929 cells as compared to PFA-fixed untreated macrophages. PFA-fixed cisplatin-treated macrophages also enhanced thymocyte proliferation. These results suggest that cisplatin treatment of murine macrophages also results in increased expression of membrane-associated lL- 1 and TNF activity.

AB - Supernatants collected from cisplatin-treated macrophages demonstrated enhanced cytotoxicity against actinomycin-D-treated L929 cells and also enhanced the thymocyte proliferation in response to concanavalin A, showing that cisplatin-treated macrophages release interleukin-1 (IL-1) and tumor necrosis factor (TNF) into the culture supernatant. The supernatant collected from untreated macrophages showed little TNF and IL-1 activity. The release of TNF and IL-1 was observed to be dependent on the dose and duration of cisplatin treatment. Medium alone containing cisplatin did not enhance thymocyte proliferation and had little cytotoxic effect on actinomycin-D-treated L929 cells. Cisplatin-treated macrophage culture supernatants were chromatographed over a Superose 12 column on an FPLC system. TNF activity eluted in two major peaks with apparent molecular weights of 50-55 and 15-20 kilodaltons, respectively. The kinetics of IL-1 release was also studied. Maximum production and release of IL-1 were observed up to 24 h after cisplatin treatment and then gradually declined. Freeze-thaw lysates of cisplatin-treated macrophages also showed enhanced IL-1 activity. Paraformaldehyde (PFA)-fixed cisplatin-treated macrophages showed significantly enhanced cytotoxic activity against L929 cells as compared to PFA-fixed untreated macrophages. PFA-fixed cisplatin-treated macrophages also enhanced thymocyte proliferation. These results suggest that cisplatin treatment of murine macrophages also results in increased expression of membrane-associated lL- 1 and TNF activity.

UR - http://www.scopus.com/inward/record.url?scp=0025910607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025910607&partnerID=8YFLogxK

M3 - Article

C2 - 1881399

AN - SCOPUS:0025910607

VL - 10

SP - 105

EP - 116

JO - Natural Immunity and Cell Growth Regulation

JF - Natural Immunity and Cell Growth Regulation

SN - 0254-7600

IS - 2

ER -